Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy

This study has been terminated.
(low enrolling participants)
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Ji-youn Han, National Cancer Center, Korea
ClinicalTrials.gov Identifier:
NCT01159327
First received: July 8, 2010
Last updated: November 9, 2015
Last verified: November 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2013
  Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)